安科生物签署PA3-17注射液产品独家代理框架协议

Core Viewpoint - Anke Bio (安科生物) has entered a strategic partnership with Boshengji Pharmaceutical Technology (博生吉医药科技) to exclusively distribute the PA3-17 injection product in Greater China, which is a CAR-T cell therapy targeting CD7 for treating certain blood cancers [1] Group 1: Partnership Details - Anke Bio signed a framework agreement for exclusive agency rights regarding the PA3-17 injection product on November 11 [1] - The agreement includes provisions for long-term cooperation in sales and promotion of the PA3-17 injection in the Greater China market [1] - A formal exclusive agency agreement will be signed after the product's market application is submitted [1] Group 2: Product Information - PA3-17 injection is the first globally approved CAR-T cell therapy targeting CD7, developed by Boshengji's subsidiary [1] - The initial indication for PA3-17 is for adult patients with relapsed or refractory CD7-positive hematologic malignancies [1] - The product has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) and is currently in critical Phase II clinical trials [1] Group 3: Future Collaboration - Boshengji has committed to prioritizing Anke Bio as the exclusive agency for future product launches [1] - Anke Bio will be responsible for the promotion and sales of these products post-launch [1]